Stan Smith Purchases 13,740 Shares of MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Stan Smith bought 13,740 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were purchased at an average cost of $1.20 per share, with a total value of $16,488.00. Following the purchase, the director directly owned 4,580 shares of the company’s stock, valued at approximately $5,496. This represents a -150.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Stan Smith also recently made the following trade(s):

• On Tuesday, November 25th, Stan Smith bought 15,000 shares of MAIA Biotechnology stock. The shares were acquired at an average cost of $0.98 per share, with a total value of $14,700.00.
• On Monday, November 24th, Stan Smith purchased 10,000 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $0.99 per share, for a total transaction of $9,900.00.
• On Wednesday, October 1st, Stan Smith purchased 19,230 shares of MAIA Biotechnology stock. The stock was bought at an average cost of $1.30 per share, for a total transaction of $24,999.00.

MAIA Biotechnology Stock Performance

Shares of NYSEAMERICAN:MAIA opened at $1.38 on Thursday. The company has a market capitalization of $51.10 million and a PE ratio of -1.89. The stock has a fifty day moving average of $1.27 and a 200-day moving average of $1.53. MAIA Biotechnology, Inc. has a one year low of $0.87 and a one year high of $2.74.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its earnings results on Friday, November 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.08). As a group, research analysts forecast that MAIA Biotechnology, Inc. will post -1.3 EPS for the current fiscal year.

Institutional Trading of MAIA Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC increased its position in shares of MAIA Biotechnology by 3.6% in the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after acquiring an additional 7,746 shares in the last quarter. Centerpoint Advisory Group purchased a new stake in shares of MAIA Biotechnology in the 2nd quarter valued at approximately $28,000. Marshall Wace LLP acquired a new position in MAIA Biotechnology in the 2nd quarter worth approximately $29,000. Jane Street Group LLC purchased a new position in MAIA Biotechnology during the 2nd quarter worth approximately $52,000. Finally, Centric Wealth Management grew its position in MAIA Biotechnology by 740.2% during the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock worth $1,032,000 after purchasing an additional 505,150 shares in the last quarter. Institutional investors and hedge funds own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.